---
title: "Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293392778.md"
description: "Goldman Sachs maintained a Buy rating on Denali Therapeutics (DNLI) with a $41.00 price target, despite shares closing at $22.90. The stock holds a Strong Buy consensus with an average target of $34.82, implying 52% upside. Additionally, Deutsche Bank assigned a Buy rating with a $35.00 target in a July 16 report."
datetime: "2026-07-21T22:40:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293392778.md)
  - [en](https://longbridge.com/en/news/293392778.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293392778.md)
---

# Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI)

Goldman Sachs analyst maintained a Buy rating on Denali Therapeutics yesterday and set a price target of $41.00. The company’s shares closed today at $22.90.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $34.82, representing a 52.05% upside. In a report released on July 16, Deutsche Bank also assigned a Buy rating to the stock with a $35.00 price target.

### Related Stocks

- [DNLI.US](https://longbridge.com/en/quote/DNLI.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)

## Related News & Research

- [Groupama Asset Managment Grows Stock Position in Denali Therapeutics Inc. $DNLI](https://longbridge.com/en/news/294581286.md)
- [Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return](https://longbridge.com/en/news/293133442.md)
- [Viking Therapeutics (VKTX) Receives a Buy from Jefferies](https://longbridge.com/en/news/294386403.md)
- [Stifel Nicolaus Keeps Their Buy Rating on Viking Therapeutics (VKTX)](https://longbridge.com/en/news/294373097.md)
- [Viking Therapeutics: Why This Clinical-Stage, Licensed-Technology Play Is a Highly Speculative Bet for Equity Investors](https://longbridge.com/en/news/294468534.md)